Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Vertex Pharmaceuticals

Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?

Vertex Pharmaceuticals has outperformed the Nasdaq over the past year, and analysts remain moderately bullish about the stock's prospects.

Barchart

Are Wall Street Analysts Bullish on Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has outperformed the broader market in 2024 but Wall Street analysts remain cautiously bullish about the stock's potential.

Barchart

Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?

After a solid first-quarter earnings report, Vertex Pharmaceuticals (VRTX) comfortably topped analysts’ earnings and revenue estimates in the first quarter. But should investors consider adding the stock to their portfolio now? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

This Could Be the Next Blockbuster Drug Stock to Buy

Vertex Pharmaceuticals just released data from its experimental drug to relieve pain, with no risk of addiction and very few side effects. This opioid alternative could give Vertex - already a powerhouse in the cystic fibrosis segment - another blockbuster drug to add to its portfolio.

Barchart

Stocks Surge on FOMC Meeting Results

What you need to know… The S&P 500 Index ($SPX ) (SPY ) is up +1.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.2%. Stocks are surging this afternoon, with the S&P 500 and...

Barchart

Stocks Slightly Higher Going into FOMC Meeting Results

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.06%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.30%. Stocks this morning are mixed, with the S&P 500...

Barchart

US approves two gene therapies for sickle cell disease

The U.S. Food and Drug Administration on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.

The Hindu

Read news from The Economist, FT, and more,
with one subscription

The First CRISPR Gene Therapy Was Finally Approved In The US — Here’s How It Works

Using the gene editing tool CRISPR, the new therapy promises a cure for those with sickle cell anemia and beta thalassemia, but cost could be a barrier to care.

Inverse

Vertex Pharmaceuticals (VRTX) Post-Earnings Analysis: Is It Time to Buy the Stock?

After a solid third-quarter earnings report, does Vertex Pharmaceuticals (VRTX) deserve a place in your portfolio? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

3 Stocks to Buy With Rising Recession and Rate Risk

The stock market continues to be a challenging environment with rising rates a potent headwind. So far, the economy has been stable enough so that earnings growth has not contracted, but this is unlikely to persist the longer the Fed stays hawkish. This article discusses characteristics of stocks that are…

StockNews.com

Vertex Pharmaceuticals Unusual Options Activity For October 27

A whale with a lot of money to spend has taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 13 strange trades.

Benzinga

3 Stocks to Ride the Bear Market Rally

Stocks could be embarking on another bear market rally despite a plethora of challenges. One factor is we are entering a seasonally bullish period of the year. Another is the bullish technical setup following the undercut and recovery of the mid-June lows. 3 stocks that investors should consider buying to…

StockNews.com

This Biotech Breakout Star is Our Growth Stock of the Week

Vertex Pharmaceuticals (VRTX) is a high-quality biotech stock that is quite cheap with impressive growth prospects. Read on to find out why it’s our growth stock of the week….

StockNews.com

3 Stocks to Buy With Rising Recession Risk, Increasing Geopolitical Tensions

Despite the bear market rally, the market is facing serious risks due to rising recession risk and increasing geopolitical tensions. Here are 3 defensive picks to help investors outperform in this tricky environment: Lockheed Martin (LMT), Vertex Pharmaceuticals (VRTX), and Elevance Health (ELVH).

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Analyzing Vertex Pharmaceuticals's Short Interest

Vertex Pharmaceuticals's (NASDAQ:VRTX) short percent of float has fallen 11.26% since its last report. The company recently reported that it has 3.42 million shares sold short, which is 1.34% of all regular shares that are available for trading.

StockNews.com

VRTX is the Growth Stock of the Week

The market is in a tough place with stubbornly high inflation, a hawkish Fed, and a slowing economy. These conditions are tough for most stocks, but pharmaceuticals are an exception. One of the top companies in the space is Vertex Pharmaceuticals (VRTX). Read on to find out why it's our…

Benzinga

$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 8.19% on an annualized basis producing an average annual return of 15.06%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.67 billion.

Benzinga

Expert Ratings for Vertex Pharmaceuticals

Over the past 3 months, 8 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Vertex Pharma Gains FDA Breakthrough Therapy Designation For Kidney Disease Drug

Vertex Pharmaceuticals (NASDAQ: VRTX) received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate inaxaplin (VX-147) for the treatment of patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS).

Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 4.83% on an annualized basis producing an average annual return of 16.83%. Currently, Vertex Pharmaceuticals has a market capitalization of $68.84 billion.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022

Upgrades

Benzinga

What 5 Analyst Ratings Have To Say About Vertex Pharmaceuticals

Over the past 3 months, 5 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

StockNews.com

2 Recession Stocks to Buy Right Now

Multi-decade-high inflation and aggressive Fed rate increases might push the economy into a recession. So, investors looking to mitigate a market downturn should invest in Dollar Tree (DLTR) and Vertex Pharmaceuticals (VRTX), as they could deliver stable returns because their businesses enjoy a near-inelastic demand.

Benzinga

Analyst Ratings for Vertex Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Analyzing Vertex Pharmaceuticals's Short Interest

Vertex Pharmaceuticals's (NASDAQ:VRTX) short percent of float has risen 18.8% since its last report. The company recently reported that it has 4.01 million shares sold short, which is 1.58% of all regular shares that are available for trading.

1 2 3

People

Jaimini DesaiJaimini Desai

59 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.